SCHEMBL410544

SCHEMBL410544

COc1ccc(NCC(F)Cn2c3ccc(Br)cc3c3cc(Br)ccc32)cc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSPO P30536 3/20 0.78
CYP1A2 P05177 2/20 0.62
CYP2C19 P33261 2/20 0.62
OPRM1 P35372 1/20 0.62
DNM1 Q05193 7/20 0.52
MAPT P10636 8/20 0.45
GAA P10253 4/20 0.45
KMT2A Q03164 4/20 0.45
ALDH1A1 P00352 4/20 0.45
MEN1 O00255 3/20 0.45
HTT P42858 2/20 0.45
HPGD P15428 2/20 0.45
MAPK1 P28482 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.41
PIK3R1 P27986 1/20 0.38
PIK3CA P42336 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL409626 0.87 TSPO (1.00) TSPOCYP1A2CYP2C19OPRM1DNM1
SCHEMBL10287450 0.87 TSPO (1.00) TSPOCYP1A2CYP2C19OPRM1DNM1
SCHEMBL18806386 0.87 TSPO (1.00) TSPOCYP1A2CYP2C19OPRM1DNM1
SCHEMBL410057 0.87 TSPO (1.00) TSPOCYP1A2CYP2C19OPRM1DNM1
SCHEMBL410188 0.87 TSPO (1.00) TSPOCYP1A2CYP2C19OPRM1DNM1
SCHEMBL10253727 0.87 TSPO (0.59) TSPOCYP1A2CYP2C19OPRM1DNM1
SCHEMBL19559315 0.86 TSPO (0.62) TSPOCYP1A2CYP2C19OPRM1DNM1
SCHEMBL410678 0.86 DNM1 (0.72) TSPOCYP1A2CYP2C19OPRM1DNM1
SCHEMBL408200 0.85 TSPO (0.61) TSPOCYP1A2CYP2C19OPRM1DNM1
SCHEMBL410170 0.84 DNM1 (0.72) TSPOCYP1A2CYP2C19OPRM1DNM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180318255-A1 Pro-Neurogenic Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2018-11-08 US claimed
EP-2590647-B1 PRO-NEUROGENIC COMPOUNDS UNIV TEXAS (US) 2017-11-08 EP claimed
US-20170157092-A1 Anti-depression Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2017-06-08 US claimed
US-9616048-B2 Anti-depression compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2017-04-11 US claimed
US-20160362372-A1 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2016-12-15 US claimed
US-9446042-B2 Pro-neurogenic compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2016-09-20 US claimed
US-20160206596-A1 Anti-depression Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2016-07-21 US claimed
US-9162980-B2 Anti-depression compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2015-10-20 US claimed
US-20150290195-A1 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2015-10-15 US claimed
EP-2925129-A1 PRO-NEUROGENIC COMPOUNDS Board of Regents of the University of Texas System (US) 2015-10-07 EP claimed
US-20130190273-A1 Methods for Treating Amyotrophic Lateral Sclerosis Using Pro-Neurogenic Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2013-07-25 US claimed
US-20130184301-A1 Methods of Treating Post-Traumatic Stress Disorder Using Pro-Neurogenic Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2013-07-18 US claimed
US-20130184300-A1 Methods of Treating Traumatic Brain Injury Using Pro-Neurogenic Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2013-07-18 US claimed
US-20130184271-A1 Methods for Treating Parkinson's Disease Using Pro-Neurogenic Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2013-07-18 US claimed
EP-2590647-A2 PRO-NEUROGENIC COMPOUNDS Board of Regents of the University of Texas System (US) 2013-05-15 EP claimed
US-20130040977-A1 Pro-Neurogenic Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2013-02-14 US claimed
US-8362277-B2 Pro-neurogenic compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2013-01-29 US claimed
US-20120022096-A1 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-01-26 US claimed
WO-2012006419-A2 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-01-12 WO claimed
US-20110003836-A1 Pro-Neurogenic Compounds BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2011-01-06 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130184301-A1 Methods of Treating Post-Traumatic Stress Disorder Using Pro-Neurogenic Compounds BDNF, GAP43, DCX TSPO 478/4885CYP1A2 4729/4885CYP2C19 4839/4885
US-20130184271-A1 Methods for Treating Parkinson's Disease Using Pro-Neurogenic Compounds BDNF, GAP43, NES TSPO 2397/4885CYP1A2 4428/4885CYP2C19 4643/4885
US-20120022096-A1 PRO-NEUROGENIC COMPOUNDS BDNF, GAP43, DCX TSPO 2470/4885CYP1A2 4486/4885CYP2C19 4751/4885
US-20130190273-A1 Methods for Treating Amyotrophic Lateral Sclerosis Using Pro-Neurogenic Compounds BDNF, GAP43, DCX TSPO 2200/4885CYP1A2 4556/4885CYP2C19 4764/4885
US-20180318255-A1 Pro-Neurogenic Compounds BDNF, GAP43, DCX TSPO 2470/4885CYP1A2 4486/4885CYP2C19 4751/4885
US-20150290195-A1 PRO-NEUROGENIC COMPOUNDS DCX, GAP43, BDNF TSPO 826/4885CYP1A2 4719/4885CYP2C19 4875/4885
US-20130040977-A1 Pro-Neurogenic Compounds BDNF, GAP43, DCX TSPO 2470/4885CYP1A2 4486/4885CYP2C19 4751/4885
US-20110003836-A1 Pro-Neurogenic Compounds DCX, GAP43, BDNF TSPO 794/4885CYP1A2 4709/4885CYP2C19 4868/4885
US-20130184300-A1 Methods of Treating Traumatic Brain Injury Using Pro-Neurogenic Compounds DCX, GAP43, BDNF TSPO 980/4885CYP1A2 4708/4885CYP2C19 4863/4885
US-20160362372-A1 PRO-NEUROGENIC COMPOUNDS DCX, GAP43, BDNF TSPO 826/4885CYP1A2 4719/4885CYP2C19 4875/4885
US-20160206596-A1 Anti-depression Compounds BDNF, DCX, GAP43 TSPO 2600/4885CYP1A2 4439/4885CYP2C19 4750/4885
US-20170157092-A1 Anti-depression Compounds BDNF, DCX, GAP43 TSPO 2600/4885CYP1A2 4439/4885CYP2C19 4750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.